amifostine anhydrous has been researched along with Blood Diseases in 10 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine." | 2.69 | [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer]. ( Pawlicki, M; Rolski, J; Rychlik, U; Wiczyńska, B, 1998) |
| " It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy." | 2.39 | [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. ( Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanat, O | 1 |
| Evrensel, T | 1 |
| Baran, I | 1 |
| Coskun, H | 1 |
| Zarifoglu, M | 1 |
| Turan, OF | 1 |
| Kurt, E | 1 |
| Demiray, M | 1 |
| Gonullu, G | 1 |
| Manavoglu, O | 1 |
| Danilatou, V | 1 |
| Dimitriou, H | 1 |
| Stiakaki, E | 1 |
| Kalmanti, M | 1 |
| Wrembel-Wargocka, J | 1 |
| Jabłońska, H | 1 |
| Chomiczewski, K | 1 |
| Kusenda, Z | 1 |
| Kerger, J | 1 |
| Awada, A | 1 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Pawlicki, M | 1 |
| Rolski, J | 1 |
| Wiczyńska, B | 1 |
| Rychlik, U | 1 |
| Raza, A | 1 |
| Qawi, H | 1 |
| Lisak, L | 1 |
| Andric, T | 1 |
| Dar, S | 1 |
| Andrews, C | 1 |
| Venugopal, P | 1 |
| Gezer, S | 1 |
| Gregory, S | 1 |
| Loew, J | 1 |
| Robin, E | 1 |
| Rifkin, S | 1 |
| Hsu, WT | 1 |
| Huang, RW | 1 |
| Sriswasdi, C | 1 |
| Jootar, S | 1 |
| Giles, FJ | 1 |
| Hartmann, JT | 1 |
| von Vangerow, A | 1 |
| Fels, LM | 1 |
| Knop, S | 1 |
| Stolte, H | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Tognella, S | 1 |
3 reviews available for amifostine anhydrous and Blood Diseases
| Article | Year |
|---|---|
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Topics: Amifostine; Antineoplastic Agents; Hematologic Diseases; Humans; Kidney Diseases; Neoplasms; Nervous | 1996 |
Amifostine and hematologic effects.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose- | 2000 |
Pharmacological interventions to reduce platinum-induced toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Cisplatin; Ditiocarb; Fluid Therapy; Glutathione; Hematolog | 1990 |
5 trials available for amifostine anhydrous and Blood Diseases
| Article | Year |
|---|---|
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
[Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1998 |
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
2 other studies available for amifostine anhydrous and Blood Diseases
| Article | Year |
|---|---|
Amifostine as differentiating agent in cord blood and bone marrow cultures from children with hematological disorders.
Topics: Amifostine; Bone Marrow Cells; Case-Control Studies; Cell Culture Techniques; Cell Differentiation; | 2004 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols | 2000 |